The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Molecular pathogenesis of multiple myeloma and its premalignant precursor
Open accessAbstract
Multiple myeloma is a monoclonal tumor of plasma cells, and its development is preceded by a premalignant tumor with which it shares genetic abnormalities, including universal dysregulation of the cyclin D/retinoblastoma (cyclin D/RB) pathway. A complex interaction with the BM microenvironment, characterized by activation of osteoclasts and suppression of osteoblasts, leads to lytic bone disease. Intratumor genetic heterogeneity, which occurs in addition to intertumor heterogeneity, contributes to the rapid emergence of drug resistance in high-risk disease. Despite recent therapeutic advances, which have doubled the median survival time, myeloma continues to be a mostly incurable disease. Here we review the current understanding of myeloma pathogenesis and insight into new therapeutic strategies provided by animal models and genetic screens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pichiorri, F., Suh, S.-S., Rocci, A., De Luca, L., Taccioli, C., Santhanam, R., Zhou, W., Benson, D. M., Hofmainster, C., Alder, H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.005 · Cited by 436
RetractedSiegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Raje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Initial genome sequencing and analysis of multiple myeloma
Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,433
Self-citationPrevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423 · cited 1×
“Monoclonal gammopathy of undetermined significance is a common premalignant tumor that precedes MM Monoclonal gammopathy of undetermined significance (MGUS) has a prevalence of 4% in Caucasians over the age of 50 (6, 7).”
The molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,133
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
Keats, J. J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.-J., Van Wier, S., Tiedemann, R., Shi, C.-X., Sebag, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.003 · Cited by 983
Self-citationAnnunziata, C. M., Davis, R. E., Demchenko, Y., Bellamy, W., Gabrea, A., Zhan, F., Lenz, G., Hanamura, I., Wright, G., Xiao, W., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.004 · Cited by 952
Self-citationUnderstanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Kyle, R. A., Durie, B. G. M., Rajkumar, S. V., Landgren, O., Blade, J., Merlini, G., Kröger, N., Einsele, H., Vesole, D. H., Dimopoulos, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.60 · Cited by 888
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Fonseca, R., Bergsagel, P. L., Drach, J., Shaughnessy, J., Gutierrez, N., Stewart, A. K., Morgan, G., Van Ness, B., Chesi, M., Minvielle, S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.174 · Cited by 886
Self-citationMultiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818
Self-citationIRF4 addiction in multiple myeloma
Shaffer, A. L., Emre, N. C. T., Lamy, L., Ngo, V. N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. (2008) · Nature · doi:10.1038/nature07064 · Cited by 730
Rajkumar, S. V., Kyle, R. A., Therneau, T. M., Melton, L. J., Bradwell, A. R., Clark, R. J., Larson, D. R., Plevak, M. F., Dispenzieri, A., & Katzmann, J. A. (2005) · Blood · doi:10.1182/blood-2005-03-1038 · Cited by 702
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
Bergsagel, P. L., Kuehl, W. M., Zhan, F., Sawyer, J., Barlogie, B., & Shaughnessy, J. (2005) · Blood · doi:10.1182/blood-2005-01-0034 · Cited by 698
Self-citationClonal competition with alternating dominance in multiple myeloma
Keats, J. J., Chesi, M., Egan, J. B., Garbitt, V. M., Palmer, S. E., Braggio, E., Van Wier, S., Blackburn, P. R., Baker, A. S., Dispenzieri, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405985 · Cited by 637
Self-citationHaigis, K. M., Kendall, K. R., Wang, Y., Cheung, A., Haigis, M. C., Glickman, J. N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.115 · Cited by 610
Pérez-Persona, E., Vidriales, M.-B., Mateo, G., García-Sanz, R., Mateos, M.-V., de Coca, A. G., Galende, J., Martín-Nuñez, G., Alonso, J. M., de las Heras, N., et al. (2007) · Blood · doi:10.1182/blood-2007-05-088443 · Cited by 579
A monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J., Verma, P., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 569
Self-citationMicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
Pichiorri, F., Suh, S.-S., Ladetto, M., Kuehl, M., Palumbo, T., Drandi, D., Taccioli, C., Zanesi, N., Alder, H., Hagan, J. P., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806202105 · Cited by 563
Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma
Bergsagel, P. L., & Kuehl, W. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.021 · Cited by 556
Self-citationClonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
Matsui, W., Wang, Q., Barber, J. P., Brennan, S., Smith, B. D., Borrello, I., McNiece, I., Lin, L., Ambinder, R. F., Peacock, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3096 · Cited by 539
Mateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70187-x · Cited by 458
Dispenzieri, A., Kyle, R. A., Katzmann, J. A., Therneau, T. M., Larson, D., Benson, J., Clark, R. J., Melton, L. J., Gertz, M. A., Kumar, S. K., et al. (2008) · Blood · doi:10.1182/blood-2007-08-108357 · Cited by 433
Avet-Loiseau, H., Leleu, X., Roussel, M., Moreau, P., Guerin-Charbonnel, C., Caillot, D., Marit, G., Benboubker, L., Voillat, L., Mathiot, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3945 · Cited by 424
MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites
Pei, H., Zhang, L., Luo, K., Qin, Y., Chesi, M., Fei, F., Bergsagel, P. L., Wang, L., You, Z., & Lou, Z. (2011) · Nature · doi:10.1038/nature09658 · Cited by 408
Self-citationDispenzieri, A., Katzmann, J. A., Kyle, R. A., Larson, D. R., Melton, L. J., Colby, C. L., Therneau, T. M., Clark, R., Kumar, S. K., Bradwell, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60482-5 · Cited by 394
Chesi, M., Robbiani, D. F., Sebag, M., Chng, W. J., Affer, M., Tiedemann, R., Valdez, R., Palmer, S. E., Haas, S. S., Stewart, A. K., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.007 · Cited by 393
Self-citationHurt, E. M., Wiestner, A., Rosenwald, A., Shaffer, A. L., Campo, E., Grogan, T., Bergsagel, P. L., Kuehl, W. M., & Staudt, L. M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00019-4 · Cited by 377
Self-citationA compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value
Walker, B. A., Leone, P. E., Chiecchio, L., Dickens, N. J., Jenner, M. W., Boyd, K. D., Johnson, D. C., Gonzalez, D., Dagrada, G. P., Protheroe, R. K. M., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279596 · Cited by 365
Martinez-Garcia, E., Popovic, R., Min, D.-J., Sweet, S. M. M., Thomas, P. M., Zamdborg, L., Heffner, A., Will, C., Lamy, L., Staudt, L. M., et al. (2011) · Blood · doi:10.1182/blood-2010-07-298349 · Cited by 360
Neben, K., Lokhorst, H. M., Jauch, A., Bertsch, U., Hielscher, T., van der Holt, B., Salwender, H., Blau, I. W., Weisel, K., Pfreundschuh, M., et al. (2012) · Blood · doi:10.1182/blood-2011-09-379164 · Cited by 356
Genetic aberrations and survival in plasma cell leukemia
Tiedemann, R. E., Gonzalez-Paz, N., Kyle, R. A., Santana-Davila, R., Price-Troska, T., Van Wier, S. A., Chng, W. J., Ketterling, R. P., Gertz, M. A., Henderson, K., et al. (2008) · Leukemia · doi:10.1038/leu.2008.4 · Cited by 349
Self-citationMorgan, G. J., Gregory, W. M., Davies, F. E., Bell, S. E., Szubert, A. J., Brown, J. M., Coy, N. N., Cook, G., Russell, N. H., Rudin, C., et al. (2012) · Blood · doi:10.1182/blood-2011-06-357038 · Cited by 331
Broyl, A., Hose, D., Lokhorst, H., de Knegt, Y., Peeters, J., Jauch, A., Bertsch, U., Buijs, A., Stevens-Kroef, M., Beverloo, H. B., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261032 · Cited by 329
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors
Avet-Loiseau, H., Gerson, F., Magrangeas, F., Minvielle, S., Harousseau, J.-L., & Bataille, R. (2001) · Blood · doi:10.1182/blood.v98.10.3082 · Cited by 289
Trudel, S., Li, Z. H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C., & Stewart, A. K. (2005) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 289
Classical and/or alternative NF-κB pathway activation in multiple myeloma
Demchenko, Y. N., Glebov, O. K., Zingone, A., Keats, J. J., Bergsagel, P. L., & Kuehl, W. M. (2010) · Blood · doi:10.1182/blood-2009-09-243535 · Cited by 288
Self-citationPrognostic Significance of Copy-Number Alterations in Multiple Myeloma
Avet-Loiseau, H., Li, C., Magrangeas, F., Gouraud, W., Charbonnel, C., Harousseau, J.-L., Attal, M., Marit, G., Mathiot, C., Facon, T., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6136 · Cited by 276
Chng, W.-J., Huang, G. F., Chung, T. H., Ng, S. B., Gonzalez-Paz, N., Troska-Price, T., Mulligan, G., Chesi, M., Bergsagel, P. L., & Fonseca, R. (2011) · Leukemia · doi:10.1038/leu.2011.53 · Cited by 270
Self-citationWalker, B. A., Wardell, C. P., Chiecchio, L., Smith, E. M., Boyd, K. D., Neri, A., Davies, F. E., Ross, F. M., & Morgan, G. J. (2011) · Blood · doi:10.1182/blood-2010-04-279539 · Cited by 267
Anderson, K. C., & Carrasco, R. D. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130249 · Cited by 258
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38017 · Cited by 255
Chesi, M., Matthews, G. M., Garbitt, V. M., Palmer, S. E., Shortt, J., Lefebure, M., Stewart, A. K., Johnstone, R. W., & Bergsagel, P. L. (2012) · Blood · doi:10.1182/blood-2012-02-412783 · Cited by 214
Self-citationLatest advances and current challenges in the treatment of multiple myeloma
Mahindra, A., Laubach, J., Raje, N., Munshi, N., Richardson, P. G., & Anderson, K. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.15 · Cited by 201
Hose, D., Reme, T., Hielscher, T., Moreaux, J., Messner, T., Seckinger, A., Benner, A., Shaughnessy, J. D., Barlogie, B., Zhou, Y., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.030296 · Cited by 199
Morgan, G. J., Davies, F. E., Gregory, W. M., Russell, N. H., Bell, S. E., Szubert, A. J., Coy, N. N., Cook, G., Feyler, S., Byrne, J. L., et al. (2011) · Blood · doi:10.1182/blood-2011-02-338665 · Cited by 198
Marango, J., Shimoyama, M., Nishio, H., Meyer, J. A., Min, D.-J., Sirulnik, A., Martinez-Martinez, Y., Chesi, M., Bergsagel, P. L., Zhou, M.-M., et al. (2008) · Blood · doi:10.1182/blood-2007-06-092122 · Cited by 197
Self-citationAvet-Loiseau, H., Daviet, A., Brigaudeau, C., Callet-Bauchu, E., Terré, C., Lafage-Pochitaloff, M., Désangles, F., Ramond, S., Talmant, P., & Bataille, R. (2001) · Blood · doi:10.1182/blood.v97.3.822 · Cited by 185
Boyd, K. D., Ross, F. M., Walker, B. A., Wardell, C. P., Tapper, W. J., Chiecchio, L., Dagrada, G., Konn, Z. J., Gregory, W. M., Jackson, G. H., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1791 · Cited by 174
Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases
Smadja, N.-V., Fruchart, C., Isnard, F., Louvet, C., Dutel, J.-L., Cheron, N., Grange, M.-J., Monconduit, M., & Bastard, C. (1998) · Leukemia · doi:10.1038/sj.leu.2401041 · Cited by 168
Pineda‐Roman, M., Zangari, M., Haessler, J., Anaissie, E., Tricot, G., Van Rhee, F., Crowley, J., Shaughnessy, J. D., & Barlogie, B. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06921.x · Cited by 166
Rasmussen, T., Kuehl, M., Lodahl, M., Johnsen, H. E., & Dahl, I. M. S. (2005) · Blood · doi:10.1182/blood-2004-03-0833 · Cited by 163
Clinical and biological significance of RAS mutations in multiple myeloma
Chng, W. J., Gonzalez-Paz, N., Price-Troska, T., Jacobus, S., Rajkumar, S. V., Oken, M. M., Kyle, R. A., Henderson, K. J., Van Wier, S., Greipp, P., et al. (2008) · Leukemia · doi:10.1038/leu.2008.142 · Cited by 161
Morgan, G. J., Davies, F. E., Gregory, W. M., Bell, S. E., Szubert, A. J., Navarro Coy, N., Cook, G., Feyler, S., Johnson, P. R. E., Rudin, C., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.043372 · Cited by 160
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug
Hu, J., Handisides, D. R., Valckenborgh, E. V., Raeve, H. D., Menu, E., Broek, I. V., Liu, Q., Sun, J. D., Camp, B. V., Hart, C. P., et al. (2010) · Blood · doi:10.1182/blood-2010-02-269126 · Cited by 152
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
Lodé, L., Eveillard, M., Trichet, V., Soussi, T., Wuillème, S., Richebourg, S., Magrangeas, F., Ifrah, N., Campion, L., Traullé, C., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.023697 · Cited by 152
Yata, K., & Yaccoby, S. (2004) · Leukemia · doi:10.1038/sj.leu.2403513 · Cited by 143
Characterization of MYC Translocations in Multiple Myeloma Cell Lines
Dib, A., Gabrea, A., Glebov, O. K., Bergsagel, P. L., & Kuehl, W. M. (2008) · JNCI Monographs · doi:10.1093/jncimonographs/lgn011 · Cited by 137
Self-citationEnhancement of clonogenicity of human multiple myeloma by dendritic cells
Kukreja, A., Hutchinson, A., Dhodapkar, K. M., Mazumder, A., Vesole, D. H., Angitapalli, R., Jagannath, S., & Dhodapkar, M. V. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052136 · Cited by 135
Raja, K. R. M., Kovářová, L., & Hájek, R. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08121.x · Cited by 127
The immortality of humoral immunity
Elgueta, R., de Vries, V. C., & Noelle, R. J. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00924.x · Cited by 123
Bochtler, T., Hegenbart, U., Cremer, F. W., Heiß, C., Benner, A., Hose, D., Moos, M., Bila, J., Bartram, C. R., Ho, A. D., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122101 · Cited by 119
Zingone, A., & Kuehl, W. M. (2011) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.11.003 · Cited by 115
Self-citationDrexler, H. G., & Matsuo, Y. (2000) · Leukemia Research · doi:10.1016/s0145-2126(99)00195-2 · Cited by 107
Gabrea, A., Martelli, M. L., Qi, Y., Roschke, A. V., Barlogie, B., Shaughnessy, J. D., Sawyer, J. R., & Kuehl, W. M. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20563 · Cited by 98
Self-citationTiming of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context
Chiecchio, L., Dagrada, G. P., Ibrahim, A. H., Cabanas, E. D., Protheroe, R. K. M., Stockley, D. M., Orchard, K. H., Cross, N. C. P., Harrison, C. J., Ross, F. M., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.011064 · Cited by 86
Steinbrunn, T., Stühmer, T., Gattenlöhner, S., Rosenwald, A., Mottok, A., Unzicker, C., Einsele, H., Chatterjee, M., & Bargou, R. C. (2010) · Blood · doi:10.1182/blood-2010-05-284422 · Cited by 82
Rossi, J. M., Moreaux, J., Hose, D., Requirand, G., Rose, M., Rouille, V., Nestorov, I. A., Mordenti, G., Goldschmidt, H., Ythier, A., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605241 · Cited by 76
Salhia, B., Baker, A. S., Ahmann, G. J., Auclair, D., Fonseca, R., & Carpten, J. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0282 · Cited by 76
Pathophysiology of myeloma bone disease
Esteve, F., & Roodman, G. D. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.08.003 · Cited by 74
Rasmussen, T., Haaber, J., Dahl, I. M., Knudsen, L. M., Kerndrup, G. B., Lodahl, M., Johnsen, H. E., & Kuehl, M. W. (2010) · Haematologica · doi:10.3324/haematol.2010.024778 · Cited by 55
Targeting the bone microenvironment in multiple myeloma
Roodman, G. D. (2010) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0154-7 · Cited by 48
Dib, A., Peterson, T. R., Raducha-Grace, L., Zingone, A., Zhan, F., Hanamura, I., Barlogie, B., Shaughnessy, J. D., & Kuehl, W. M. (2006) · Cell Division · doi:10.1186/1747-1028-1-23 · Cited by 40
Self-citationChiron, D., Surget, S., Maïga, S., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08904.x · Cited by 29
Mateos, M., López‐Corral, L., Hernández, M., Giraldo, P., de la Rubia, J., de Arriba, F., Rosiñol, L., Lahuerta, J. J., Palomera, L., Bargay, J., et al. (2010) · Blood · doi:10.1182/blood.v116.21.1935.1935 · Cited by 29
Zingone, A., Cultraro, C. M., Shin, D.-M., Bean, C. M., Morse, H. C., Janz, S., & Kuehl, W. M. (2010) · Leukemia · doi:10.1038/leu.2010.50 · Cited by 25
Self-citation
Cited by
Röllig, C., Knop, S., & Bornhäuser, M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 603
Targeting Bruton's tyrosine kinase in B cell malignancies
Hendriks, R. W., Yuvaraj, S., & Kil, L. P. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3702 · Cited by 552
Cho, S.-F., Anderson, K. C., & Tai, Y.-T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01821 · Cited by 294
Pathogenesis beyond the cancer clone(s) in multiple myeloma
Bianchi, G., & Munshi, N. C. (2015) · Blood · doi:10.1182/blood-2014-11-568881 · Cited by 288
Affer, M., Chesi, M., Chen, W. D., Keats, J. J., Demchenko, Y. N., Tamizhmani, K., Garbitt, V. M., Riggs, D. L., Brents, L. A., Roschke, A. V., et al. (2014) · Leukemia · doi:10.1038/leu.2014.70 · Cited by 268
Self-citation
Metadata
- Authors
- Kuehl, W. M., & Bergsagel, P. L.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-10-01
- Volume
- 122
- Issue
- 10
- Pages
- 3456-3463
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2056172893
- Cited by
- 334
- References
- 81
- FWCI
- 21.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.